Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclarion Inc WT (ACONW)

Aclarion Inc WT (ACONW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 80 K
  • Annual Income, $ -7,230 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Services

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0306 +37.91%
on 04/08/26
0.0480 -12.08%
on 03/31/26
-0.0004 (-0.94%)
since 03/17/26
3-Month
0.0306 +37.91%
on 04/08/26
0.0480 -12.08%
on 03/31/26
-0.0015 (-3.43%)
since 01/16/26
52-Week
0.0214 +97.20%
on 06/13/25
0.2333 -81.91%
on 10/13/25
-0.0031 (-6.84%)
since 04/17/25

Most Recent Stories

More News
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain

Patent covers use of AI in workflows of future products to accelerate company’s ability to scale and enhance already strong gross margins Expands intellectual property portfolio to 64 issued and...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Receives Pinnacle Award for AI Innovation

Recognition Follows 2025 HLTH Digital Health Award for Nociscan Award Winning AI Targets a Large and Costly Chronic Low Back Pain Market BROOMFIELD, Colo., April 14, 2026 (GLOBE NEWSWIRE) --...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Announces Agreement with Weill Cornell Medicine

BROOMFIELD, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc.,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Video featuring Mr. John Sutcliffe, Lead Clinician at The London Spine Clinic, highlights real-world physician experience with Nociscan in clinical practice Nearly 100 Nociscans performed at The London...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 ...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

BROOMFIELD, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc .,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion CEO Brent Ness to Attend LSI USA 2026

BROOMFIELD, Colo., March 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc .,  (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),  a commercial-stage healthcare technology company that is leveraging...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Publishes 2026 Shareholder Letter from the Chairman

Company anticipates no capital raises prior to expected value enhancing catalysts  Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo.,...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)
Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Expands availability of Nociscan in the greater Los Angeles area Reinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection...

ACONW : 0.0422 (unch)
ACON : 3.39 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.